Polarean Imaging plc (PLLWF)
| Market Cap | 17.80M |
| Revenue (ttm) | 1.87M |
| Net Income (ttm) | -8.55M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Average Volume | 13,368 |
| Open | 0.0110 |
| Previous Close | n/a |
| Day's Range | 0.0110 - 0.0110 |
| 52-Week Range | 0.0100 - 0.0520 |
| Beta | 0.11 |
| RSI | 24.80 |
| Earnings Date | May 22, 2025 |
About Polarean Imaging
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. It engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. The company also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measur... [Read more]
Financial Performance
In 2023, Polarean Imaging's revenue was $890,933, a decrease of -13.75% compared to the previous year's $1.03 million. Losses were -$11.88 million, -14.53% less than in 2022.
Financial StatementsNews
Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives
DURHAM, NC and LONDON, June 20, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging...
FDA Approves Polarean's XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation
XENOVIEW represents the first and only hyperpolarized MRI contrast agent ● FDA approved indication includes both adolescents and adults representing a significant market opportunity XENOVIEW represent...